Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030391 · ClinicalTrials.gov registry record · Phase 1
Novel Positron Emission Tomography (PET) Radiotracer to Image Phosphodiesterase-4B (PDE4B)
A Phase 1 study, sponsored by National Institute of Mental Health (NIMH).
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03030391 is a Phase 1 study that was terminated before completion, run by National Institute of Mental Health (NIMH). The registered enrollment target is 5 participants.
The verdict
NCT03030391, a Phase 1 study, was terminated before completion, sponsored by National Institute of Mental Health (NIMH).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
Background: The new drug 18F-PF-06445974 has a little radioactivity. This can be seen by a positron emission tomography (PET) scan. The drug helps researchers see a protein, PDE4B, in the brain. Looking at PDE4B in the living brain might show how it is involved in psychiatric and neurological disorders. One part of the study will look at how the study drug is distributed in the brain. Another part will study how brain measures vary. Objectives: To measure the protein PDE4B in the brain. To test how a new radioactive chemical, 18F-PF-06445974, is distributed in the body. Eligibility: Healthy adults ages 18 and older Design: Participants will have 1-3 visits over a year. Each will be 2-5 hours. Women will have a pregnancy test each time.
Interventions
- OTHER MRI
- OTHER PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-01-10 |
| Est. Completion | 2018-03-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03030391
The ClinicalTrials.gov registry entry for NCT03030391 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MRI is the first listed.
NCT03030391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03030391 about?
NCT03030391 is a clinical study titled "Novel Positron Emission Tomography (PET) Radiotracer to Image Phosphodiesterase-4B (PDE4B)". Background: The new drug 18F-PF-06445974 has a little radioactivity. This can be seen by a positron emission tomography (PET) scan. The drug helps researchers see a protein, PDE4B, in the brain. Looking at PDE4B in the living brain might show how it is involved in psychiatric and neurological disor...
What is the current status of trial NCT03030391?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-01-10. Estimated completion is 2018-03-16.
What interventions are being tested in trial NCT03030391?
The interventions under investigation include: MRI (OTHER), PET (OTHER).
Who is sponsoring clinical trial NCT03030391?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.